Viking Therapeutics: No Buyout Needed Now
- Viking Therapeutics' hit yearly lows despite strong sector expectations, as it enters pivotal trials for obesity drugs.
- The biotech announced a production deal with CordenPharma, signaling confidence in FDA approval and eliminating the need for capital-intensive manufacturing facilities.
- The $150 million prepayment deal with CordenPharma ensures production capacity ensures production capacity for 1 billion oral tablets and billions in annual revenues.
- The stock only has a market cap of $3 billion after this dip, despite the potential for billions in sales and a peer trading at 12.5x sales targets.
The obesity drug sector has taken a significant hit despite ongoing strong expectations for weight-loss drugs. The sector dip has left Viking Therapeutics, Inc. (NASDAQ:VKTX) at yearly lows just as the biotech enters pivotal trials for their obesity drugs. My investment thesis remains ultra-Bullish on the stock following the latest dip and game-changing manufacturing deal.
Read the full article on Seeking Alpha.
Disclosure: No position mentioned. Please review the disclaimer page for more details.
Comments